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Abstract 
Human hepatic flavin-containing monooxygenase 3 (hFMO3) catalyses the monooxygenation of 
carbon-bound reactive heteroatoms and plays an important role in the metabolism of drugs and 
xenobiotics. Although numerous hFMO3 allelic variants have been identified in patients and their 
biochemical properties well-characterised in vitro, the molecular mechanisms underlying loss-of-
function mutations have still not been elucidated due to lack of detailed structural information of 
hFMO3. Therefore, in this work a 3D structural model of hFMO3 was generated by homology 
modeling, evaluated by a variety of different bioinformatics tools, refined by molecular dynamics 
simulations and further assessed based on in vitro biochemical data. The molecular dynamics 
simulation results highlighted 4 flexible regions of the protein with some of them overlapping the 
data from trypsin digest. This was followed by structural mapping of 12 critical polymorphic variants 
and molecular docking experiments with five different known substrates/drugs of hFMO3 namely, 
benzydamine, sulindac sulphide, tozasertib, methimazole and trimethylamine. Localisation of these 
mutations on the hFMO3 model provided a structural explanation for their observed biological effects 
and docked models of hFMO3-drug complexes gave insights into their binding mechanism  
demonstrating that nitrogen- and sulfur-containing substrates interact with the isoalloxazine ring 
through Pi-Cation interaction and Pi-Sulfur interactions, respectively. Finally, the data presented give 
insights into the drug binding mechanism of hFMO3 which could be valuable not only for screening 
of new chemical entities but more significantly for designing of novel inhibitors of this important 
Phase I drug metabolising enzyme.  
 
Keywords: Monooxygenase, 3D model, molecular dynamics, fish odour syndrome, molecular 
docking, polymorphism  
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1. Introduction 
The mammalian flavin-containing monooxygenases (FMO) belong to the oxidoreducatase subclass 
1.14 and comprise a family of five functional enzymes that catalyse the oxygenation of a wide variety 
of nucleophilic heteroatom-containing compounds and have specific endogenous biological roles  
(Cashman and Zhang, 2006). In humans, FMO3 (hFMO3) has been described as playing a prominent 
role in the catabolism of drugs by selective oxygenation of nitrogen- and sulfur-containing 
xenobiotics resulting in their detoxification via excretion (Cashman and Zhang, 2006). The latter 
reactions are part of human hepatic Phase I drug metabolism mainly carried out by cytochromes P450. 
However, unlike cytochromes P450, the hFMO3 reaction produces few toxic metabolites and 
therefore poses considerable clinical advantages (Cashman, 2005; 2008). Moreover, in addition to its 
role in drug metabolism, FMO3 has also been shown more recently to act as an important modifier 
of human health in atherosclerosis and cholesterol/glucose/lipid metabolism (Leiser et al., 2015; 
Schugar et al., 2015). 
Certain mutations within the hFMO3 gene can lead to the abnormal drug or chemical metabolism. 
One such genetic disease, trimethylaminuria (TMAU or fish odour syndrome), is due to genetic 
polymorphisms in the hFMO3 gene that cause defective trimethylamine (TMA) N-oxygenation 
(Dolphin et al., 1997). In addition, mutations can also affect the substrate selectivity with some 
abolishing or lowering both N- or S-oxygenation capacity of the enzyme, while other mutations only 
abolish the N-oxygenation activity (Zhou and Shephard, 2006).  
In spite of growing knowledge of genetic polymorphisms in hFMO3, the molecular mechanisms 
underlying the loss of function or substrate specificity of genetic variants is still unclear due to lack 
of detailed structural information for hFMO3. However, the crystal structures of a eukaryotic FMO 
(yFMO) from Schizosaccharomyces pombe (Eswaramoorthy et al., 2006) and a prokaryotic FMO 
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(bFMO) from Methylophaga sp. Strain SK1 (Alfieri et al., 2008) have been solved recently providing 
useful templates for the construction of a hFMO3 model. In previous years our group (Sadeghi et al., 
2010) and others have published 3D models of hFMO3 (Borbás et al., 2006; Yeung et al., 2007) 
however, in most cases the templates selected were different. The goal of the present study is to build 
a hFMO3 model used for structural mapping of critical polymorphic variants to provide a structura l 
explanation for their biological effects. In addition, molecular docking is performed to investigate the 
possible molecular basis of binding of different drugs.  
 
2. Materials and methods 
2.1. Sequence analysis and molecular modeling 
The search and the identification of templates suitable for homology modeling were performed by 
BLAST (http://blast.ncbi.nlm.nih.gov/). The hFMO3 sequence (NCBI CCDS ID: CCDS1292.1) was 
defined as the target sequence, and the crystal structures of bFMO (PDB ID: 2VQ7) (Alfieri et al., 
2008) and yFMO (PDB ID: 2GV8) (Eswaramoorthy et al., 2006) served as templates. Sequence 
identities and homologies to hFMO3 are 23.0% and 40.4% for bFMO and 21.5% and 37.5% for 
yFMO, respectively. Multiple sequence alignment was performed with ClustalW (Chenna, 2003) and 
ESPript 3.0 (Gouet et al., 1999). This alignment was used for the model construction by YASARA 
Model package (Krieger and Vriend, 2002). A long insertion of 70 amino acids (D226-G295) together 
with the extended C-terminal portion which could not align to the templates were constructed by 
Phyre2 server (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) and integrated into the 
final model by YASARA (Krieger and Vriend, 2002). The quality of the obtained hFMO3 structura l 
model was evaluated using PROCHECK (http://services.mbi.ucla.edu/PROCHECK/), ProSA 
(https://prosa.services.came.sbg.ac.at/prosa.php) and ERRAT (Colovos and Yeates, 1993; 
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Wiederstein and Sippl, 2007). 
 
2.2. Molecular dynamics (MD) simulation 
The molecular dynamics simulation was performed by YASARA structure package (Krieger and 
Vriend, 2002). This software package contains all the functions needed to predict and validate 
macromolecular structures, including ligand docking and highly accurate force fields with 
knowledge-based potentials. Prior to MD simulation, the hFMO3 model was first optimized for its 
hydrogen bonding network to achieve more stable trajectories. The optimized structure was then 
placed in a simulation cell that was 10 Å larger than the protein. The force Field AMBER 03 was 
assigned and the cell was then filled with water molecules and NaCl at the physiological concentration 
of 0.9%. Counter ions were also placed in the cell, predicting pKa values and assigning protonation 
states and the temperature was set to 298K. The simulation cell was subsequently rescaled to obtain 
a density for water residues of 0.997 g/L. The initial structure was subjected to energy minimizat ion 
performing a simulated annealing minimization which moves the structure to a nearby stable energy 
minimum. Initial atom velocities were set according to a Boltzmann distribution and the molecular 
dynamics was then followed for 5 nanoseconds recording snapshots at regular time intervals of every 
25 picoseconds. The AMBER 03 force field was employed throughout all simulations. The cutoff for 
van der Waals interactions was 7.86 Å and the Particle Mesh Ewald (PME) algorithm was applied to 
compute the long range electrostatic interactions. The results of the molecular dynamics simulat ion 
were analysed with YASARA using an embedded pre-written script that, on the basis of the time 
course, is able to analyse structure stability creating a per residue table with average RMSFs and 
RMSDs from the starting structure. 
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2.3. Protein expression and purification 
E. coli JM109 cells transformed with pJL2-hFMO3 were used for the expression of hFMO3 protein 
as previously described (Catucci et al., 2012). The cells were harvested 22 h post-induction and the 
protein was extracted from membrane fractions using 1% IGEPAL and purified by Ni affinity 
chromatography. The purified protein was collected and analysed by 12.5% SDS-PAGE. Protein 
concentration was determined by spectroscopy with the peak absorbance at 450 nm and an extinct ion 
coefficient of 11900 M-1cm-1 as described previously (Catucci et al., 2012). 
2.4. Trypsin digestion 
Trypsin digestion was carried out to analyse the banding patterns of peptides generated (Coulter-
Mackie and Lian, 2008). Briefly, 116 μg hFMO3 in 80 μl phosphate buffer (pH 7.4) was mixed with 
60 μg trypsin and incubated for 2, 5, 10, 15, 30, 60, 120 min at 37 °C. At each time interval, 10 μl of 
the reaction mixture was removed and mixed with 10 μl SDS loading buffer (60 mM Tris pH 6.8/2% 
SDS/12% glycerol/0.001% bromophenol blue) and incubated at 98 °C for 10 min. All samples 
collected in this manner were subsequently subjected to SDS-PAGE analysis.  
 
2.5. Molecular docking 
Autodock version 4.0 (Goodsell and Morris, 1996) incorporated into the YASARA Structure package 
was used for molecular docking studies. Five different known substrates of hFMO3, namely 
benzydamine, methimazole, sulindac sulfide, tozasertib and trimethylamine were docked into the 
substrate binding pocket of the hFMO3 model. Each of these substrates (ligands) were initially built 
and optimized using Discovery Studio Visualizer (Dassault Systèmes, 2016) prior to the docking 
experiments. First a global docking experiment was performed by executing a total of one hund red 
runs of Global Docking centring a 15 × 15 × 15 Å simulation cell on the FAD group. In this 
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experiment, the substrate is originally outside the simulation box and is placed inside the cell by 
exploiting the Autodock algorithm, resulting in a series of binding modes classified by the binding 
energy outputs. Among these binding modes the complex protein-ligand bearing the highest binding 
energy, calculated by YASARA as the mechanical energy required for disassembling a whole into 
separate parts (where positive energies indicate stronger binding and negative energies equate to no 
binding), was selected and further refined by local docking.  After global docking the best binding 
mode (pose) was selected based on the best binding energy. The complexes were then subjected to 
999 runs of Local Docking yielding the final docked binding modes. In local docking experiments 
the ligand is within the simulation cell and the possible conformations are assayed around the starting 
pose. The results are again sorted by binding energy, and the most suitable binding mode with the 
highest binding energy was finally selected and optimized by energy minimization using YASARA. 
 
3. Results and Discussion 
3.1. Sequence alignment and homology modeling 
As mentioned earlier, currently there are only two FMO proteins with known crystal structures: one 
bacterial (bFMO) (Alfieri et al., 2008), the other from yeast (yFMO) (Eswaramoorthy et al., 2006). 
When these two protein structures are superimposed (Cα backbone) in spite of only 23.4% sequence 
identity, they present a highly conserved overall structure. The primary amino acid sequence of 
hFMO3 was aligned with the sequences of these two proteins and the FMO-identifying sequence 
motif together with the two Rossmann-fold motifs (Fraaije et al., 2002) were identified and are shown 
in Fig. 1. The latter alignment also demonstrates the lack of alignment within the insert region (S218-
I292) and C-terminal portion of hFMO3 (V501-T532). Therefore, structural models of the insert 
region and the missing C-terminal region were built separately by Phyre2 based on homology-
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searching program PSI-BLAST (position-specific iterated basic local alignment search tool). The 
result of multiple sequence alignment for insertion region shows this part is built using insertion 
regions of Baeyer-Villiger monooxygenases (PDB ID: 3GWD/96% confidence, 1W4X/96% 
confidence, 4AP3/96% confidence, 3UCL/95% confidence, 3UOY/95% confidence) as templates. 
The resulting secondary structures obtained are shown in Fig. 2B with 100% of residues of the insert 
region modelled with >90% confidence. While for the C-terminal portion, although 0% residues 
modelled at more than 90% confidence, a helix conformation was thought to be reasonable as reported 
previously (Sadeghi et al., 2010). The overall model, shown in Fig. 2A, was thus built based on the 
sequence alignment and integration of the insertion and C-terminal regions by YASARA Model 
package. Ramachandran Plot analysis (Figure S1 in the supporting Information) determined by 
PROCHECK reveals that 87.6%, 11.7% and 0.7% of the residues of the hFMO3 model are located in 
the most favoured, generously allowed and disallowed regions, respectively. The overall G-factor is 
0.01, indicating a good quality model (acceptable values of the G-factor in PROCHECK are between 
0 and −0.5, with the best models displaying values close to zero). The results of ERRAT, a method 
for discriminating between correctly and incorrectly determined fragments of protein structures based 
on characteristic atomic interaction, and ProSA (Figure S2 in the supporting Information) suggest that 
the quality of the hFMO3 structural model is satisfactory and can be used for further analysis. A 
summary of the hFMO3 model quality data gathered through different bioinformatics tools is shown 
in Table 1. 
 
Table 1. Summary of the main parameters obtained from validation of hFMO3 homology model 
through PROCHECK, ProSA and ERRAT servers. 
 
Ramachandran plot  
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Residues in most favoured and allowed regions (%) 87.6 
Residues in generously allowed regions (%) 11.7 
Residues in disallowed regions (%) 0.7 
G-factor (dihedrals) -0.21 
M/c bond lengths  
within limits (%) 100 
highlighted (%) 0 
M/c bond angles  
within limits (%) 96.6 
highlighted (%) 3.4 
Planar groups  
within limits (%) 89.9 
highlighted (%) 10.1 
G-factor (overall) 0.01 
ProSA z-score -7.73 
ERRAT score 96.367 
 
The hFMO3 model was further refined by 5 ns of MD simulations and reached structural stability 
after only 2 ns as shown in Figure 3A. The variation in RMSD for each Cα atom of the model was 
determined during the MD simulations and revealed the most flexible regions of the protein to be 
grouped in four different regions. These highly flexible regions namely V110-H150, V220-A250, 
P400-Y430 and P450-T532 are located on the solvent-accessible surface of the hFMO3 model as 
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shown in Fig. 3B. The location of these flexible regions will be discussed later and put into context 
with the in vitro experimental data presented in the trypsin digestion section. 
The final 3D generated model of hFMO3 showed two distinct domains, a smaller NADP+-binding 
domain with a larger FAD-binding domain connected through a double linker, similar to the bacterial 
and yeast FMO structures ((Eswaramoorthy et al., 2006; Alfieri et al., 2008) with the exception of the 
extra insert region (S218-I292). The hFMO3 model also shows very similar active site to those of the 
two crystallised bacterial and yeast FMOs. 
 
3.2. Structural mapping of the critical hFMO3 allelic variants 
To further evaluate the hFMO3 model and provide possible structural rationalization for the biologica l 
effects of the polymorphisms in hFMO3, twelve critical amino acids that have been previously well 
characterised (Dolphin et al., 2000; Zhang et al., 2003;Yamazaki et al., 2007; Yeung et al., 2007; 
Shimizu et al., 2012) (Table 2) were mapped onto the model and are shown in Fig. 2A. According to 
the hFMO3 model, residues: P70, P153, E158, R205, V257, E308, G421 and T488 are located at 
some distance from FAD and TMA binding pocket. Mutations at these sites may be expected to have 
little or no effect on Km for TMA, which fits reasonably well with the in vitro results shown in Table 
2. Besides, our model shows that P153 is located on the edge of substrate binding pocket and may 
affect ingress/egress of substrates (Fig. 2D). Therefore, the greatly reduced kcat of P153L mutant can 
be readily rationalised. While for E32K which completely abolishes the catalytic activity of hFMO3 
for TMA (Table 2), although not located in the catalytic pocket, E32 stabilizes FAD by hydrogen 
bonds (Fig. 2C). Therefore, the inactivity of this mutant is likely due to the poor retention of the FAD 
cofactor in the folded protein. As shown in Fig. 2D, V58, N61 and S195 are located in the catalytic 
pocket, but only N61 interacts directly with TMA through hydrogen bonding (Fig. 5D). This could 
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explain the greatly improved Km of N61S mutant. On the other hand, V58 and S195 do not make any 
direct contact with TMA (Fig. 2D and Fig. 4D) and therefore, although located in the TMA binding 
pocket, V58I and S195L have little effect on the measured Km value as summarised in Table 2. 
Furthermore, the model shows that S195 stabilizes bound NADP+ through hydrogen bonding 
interactions (Fig. 2C). Since oxidized NADP+ remains tightly bound and is involved in the 
stabilisation of the C4a-hydroperoxy-FAD intermediate that is crucial for substrate oxygenation 
(Alfieri et al., 2008; Orru et al., 2010), S195L mutation may destabilise the NADP+ binding and 
accelerate the decay of the intermediate, which is in good agreement with the dramatically reduced 
kcat for TMA (Table 2).  
The above analyses demonstrate that the 3D generated model of hFMO3 can be reliable as the 
locations of the selected variants on the model fits reasonably well with the changes reported 
previously by in vitro measurements of their kinetic constants (Table 2).  
Table 2. The ratios of kinetic constants of variants to the wild-type hFMO3 
Variant Km(variant)/Km(Wt) kcat(variant)/kcat(Wt) Reference  
E32K 0 0 Zhang et al., 2003  
V58I 0.92 0.66 Shimizu et al., 2012  
N61S 6.61 0.24 Dolphin et al., 2000  
P70L 0.92 0.51 Shimizu et al., 2012  
P153L 0.97 0.09 Yeung et al., 2007  
E158K 0.87 1.17 Yeung et al., 2007  
S195L 1 0.06 Shimizu et al., 2012  
R205C 1 0.26 Yamazaki et al., 2007  
V257M 0.87 1.43 Yeung et al., 2007  
E308G 0.94 0.78 Yeung et al., 2007  
G421V 0.97 0.55 Shimizu et al., 2012  
T488A 0.91 0.54 Shimizu et al., 2012  
 
3.3.Trypsin digestion 
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In general, limited proteolysis is usually restricted to a few specific locations on the surface of any 
given protein. Previous studies on proteins with known crystal structures have demonstrated that the 
cleavage sites are mostly at the level of loops and not alpha helices (Fontana et al., 2004). Therefore, 
limited proteolysis experiments can be used to identify the regions with highest flexibility within a 
folded protein. Limited proteolysis can be carried out by trypsin digestion, as a useful measure of 
protein folding where the crystal structure is unknown. It can cleave proteins at carboxyl side of the 
trypsin-accessible lysine and arginine residues. Here, trypsin digestion was used to evaluate the 
homology model generated by analysing the peptide patterns generated over time. Fig. 4A shows the 
trypsin digestion results, in particular the presence of a new peptide band around 47.0 kDa together 
with several smaller molecular weight bands mainly ranging from 27 to 31 kDa. The possible lysine 
or arginine cleavage sites of trypsin together with their corresponding observed bands are summarised 
in Table 3. The cleavage sites resulting in the new band around 47.0 kDa may be formed by digestion 
at several contiguous residues including K415, K416, R417 or K418. While peptide bands between 
27 kDa and 31 kDa may be the result of digestion at K265, R263, R279 and K280 which form peptides 
with 28.9 kDa, 28.7 kDa, 30.4 kDa and 30.5 kDa, respectively. The location of these lysine and 
arginine residues are shown in Fig. 4B-C which highlight the fact that these amino acids are on the 
surface, exposed to the solvent and readily accessible to trypsin. Therefore, these data give further 
experimental proof in support of the accuracy of the hFMO3 model. 
 
Table 3. The possible trypsin cleavage sites and their corresponding digestion bands produced in SDS-
PAGE. 
Cleavage site Digestion Bands 
R263 30.3 kDa   29.7 kDa 
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Moreover, in order to better understand the connection between the surface exposure and the 
flexibility of the protein structure, the results of MD simulation were compared to the trypsin 
digestion patterns. Each residue of the model was evaluated in terms of root mean square fluctuat ion 
(RMSF) throughout the MD simulation. The analysis revealed the presence of four highly flexib le 
regions (V110-H150, V220-A250, P400-Y430 and P450-T532) located on the solvent-access ib le 
surface as shown in Fig. 3B. Of these, V220-A250 is located in the insert region and close to trypsin-
accessible sites R279 and K280. The other three highly flexible regions are located in the FAD binding 
domain, and one of these, P400-Y430, contains cleavage sites K415-K418 of trypsin. The high 
flexibility and solvent-accessibility of K415-K418 make it an easy target for trypsin attack, which fits 
quite well with the results of trypsin digestion.  
 
3.4. Binding mode analysis 
To provide insights into the molecular basis of substrate binding, YASARA Structure package was 
used for the docking experiments and the results were analysed by DS Visualizer. Structure-based 
computer modelling of drug-enzyme interactions is one of the most important pillars of modern drug 
discovery (Charifson and Kuntz, 1997). The two main aims of these in silico binding studies are to 
firstly obtain reliable estimates of the affinities of the selected drugs to the protein and secondly to 
K265 29.9 kDa 29.1 kDa 
R279 30.5 kDa 28.5 kDa 
K280 31.6 kDa 28.4 kDa 
K415-K418 ~ 47 kDa ~ 13 kDa 
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analyse their mechanism of interaction (Hulme and Trevethick, 2010). To this end, the refined hFMO3 
model served as receptor and several well-characterised drugs/substrates were used as ligands. The 
five ligands used for molecular docking were prepared in DS Visualizer and optimized using Clean 
Geometry function (Fig. 5A) and include benzydamine (Castrignanò et al., 2010), a nonsteroidal anti-
inflammatory drug; methimazole, a drug used to treat hyperthyroidism; sulindac sulfide (Castrignanò 
et al., 2012), a non-steroidal anti-inflammatory drug that reduces tumour burden in human colorectal 
cancer; tozasertib (Catucci et al., 2013), a pan-Aurora kinase inhibitor for cancer treatment and, 
trimethylyamine, an organic compound found in dietary food with a “fishy” odour which if not 
metabolised by hFMO3 causes the fish odour syndrome (Dolphin et al., 1997). The best binding 
modes of each of these drugs with the highest binding energies were selected and optimized by energy 
minimization for further analysis. The docking results were analysed using non-bond interact ions 
monitor function by DS Visualizer and are shown in Fig.5B-F. The calculated theoretical binding 
energies for each of the five substrates tested are also summarized in Table 4.  
Table 4. Substrate binding energy for hFMO3 model calculated by YASARA 
Substrate Binding energy (kcal/mol) 
Tozasertib 5.74 
Sulindac sulfide 5.61 
Benzydamine 4.29 
Methimazole 3.64 
Trimethylamine 1.89 
 
As can be seen in the table, the binding energies range between 1.89 to 5.74 kcal/mol and follow the 
order Tozasertib > sulindac sulfide > benzydamine > methimazole > trimethylamine. Unfortunate ly, 
these theoretical binding energies cannot be compared to experimental results due to lack of any such 
reported data within the literature. 
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The docking results demonstrate that hydrogen bonds, electrostatic and hydrophobic interactions all 
play important roles in substrate binding. The non-bond interactions are identified by DS Visualizer 
based on mainly interatomic distance and angle constraints. Fig. 5B-F shows how residues in the 
catalytic pocket stabilise the substrates by non-bond interactions. The docking result of 
benzydamine/hFMO3 complex (Fig. 5B) shows that N61, G376 and N194 interact with substrate 
through non classical hydrogen bonds (Carbon Hydrogen Bonds (Pierce et al., 2002) and Pi-Donor 
Hydrogen Bonds (Bissantz et al., 2010)). For the binding mode of tozasertib (Fig. 5C), the substrate 
is mainly stabilised by the conventional hydrogen bond interactions (Bissantz et al., 2010) with Y331 
and L375. In the case of tozasertib, it also forms carbon hydrogen bonds (a kind of weaker hydrogen 
bond) with G330 and G376 and, a Pi-donor hydrogen bond with N194. Finally, for the 
trimethylamine/hFMO3 binding mode (Fig. 5D), the substrate only interacts with N61 and G376 
through carbon hydrogen bonds.  
The docking results also show the interactions of sulfur-containing substrates, methimazole and 
sulindac sulfide, with their surrounding amino acid residues. As shown in Fig. 5E, a Pi-donor 
hydrogen bond with N194 and conventional hydrogen bonds with N61 contribute to the stabilisat ion 
of methimazole in the catalytic pocket. In the case of sulindac sulfide (Fig. 5F), this substrate interacts 
with H149, G193 and N194 through Pi-Sigma (Ozawa et al., 2008), carbon hydrogen bond and Pi-
donor hydrogen bond interactions, respectively. 
Substrate binding modes also indicate that FAD plays a critical role in the stabilisation of substrates. 
Fig. 5B-D show that the N-oxidation sites of benzydamine, tozasertib and trimethylamine interact 
with the isoalloxazine ring through Pi-cation interactions (Gallivan and Dougherty, 1999), a kind of 
electrostatic interaction. In addition, benzydamine and trimethylamine also form Pi-Sigma 
interactions with the isoalloxazine ring. While for the S-oxidation sites of methimazole and sulindac 
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sulfide, the interaction with the isoalloxazine ring of FAD cofactor is mainly through Pi-sulfur 
interactions (Fig. 5E-F) (Ringer et al., 2007). In the case of methimazole, as seen in Fig. 5F, there is 
the additional Pi-stacking interaction (McGaughey et al., 1998) which further contributes to the 
stabilisation of the binding of this substrate.  
Taken together, the five different substrates in this study interact with residues around the binding site 
mainly through weak non-bond interactions. The nitrogen-containing substrates interact with the 
isoalloxazine ring through Pi-cation interaction, while the sulfur-containing substrates form Pi-sulfur 
interactions with the isoalloxazine ring. In the case of methimazole binding to hFMO3, the molecular 
docking results presented in this work, with Pi-stacking interactions between this substrate and the 
FAD cofactor, are very similar to the crystallography data of the co-crystals of methimazole and yeast 
FMO (PDB ID: 2GVC) (Eswaramoorthy et al., 2006) and also indole/FAD interaction in the bacterial 
FMO (PDB ID:2XVJ) (Cho et al., 2011). The latter observation is in support of the suitability of the 
hFMO3 model for in silico molecular docking applications. 
 
4. Conclusions 
In this work, a three-dimensional model of hFMO3 was generated by homology modelling with the 
help of YASARA Model package and Phyre2 using the only two available crystal structures of the 
prokaryotic and yeast FMOs. The model was further refined by 5 ns of MD simulations and evaluated 
by a variety of different bioinformatics tools, structural mapping of some critical mutation sites and 
in vitro trypsin digestion. The in vitro trypsin digestion results were in good agreement with the 
location of the four surface exposed flexible regions highlighted by the MD simulations and structura l 
mapping of polymorphic variants provide the structural rational for their biological effects. In addition, 
docking capability of the model was assessed by docking of five important drugs/substrates of this 
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human hepatic enzyme. The best binding pose of each of the latter substrates was in agreement with 
the enzymatic product i.e. either N- or S-oxide. The calculated theoretical binding energies could not 
be directly compared to experimental data due to lack of any such reported data within the literature. 
The predicted binding modes of nitrogen- and sulfur-containing substrates could be useful for better 
understanding of their binding mechanism. Finally, the model presented is reliable in terms of 3D 
structure and stereochemistry and can therefore be used in not only screening of new chemical entities  
but also in designing novel inhibitors of this enzyme which currently are not available.  
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Figure 1  
 
 
 
 
Alignment of the sequences of hFMO3, bFMO and yFMO. Conserved residues are colored in red, 
and boxed residues are semi-conserved. The residues around cofactors (NADP+ and FAD) in bFMO 
and yFMO are starred underneath. Motifs and mutated residues in patients affected by TMAU are 
also indicated. The insertion and C-terminal regions are colored in cyan. The multiple sequence 
alignment was performed with ClustalW and prepared using ESPript 3.0.   
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Figure 2 
 
 
 
 
 
 (A) Structural model of hFMO3. NADP-binding domain is light orange with FAD-binding domain 
in cyan. The insert region is colored in light blue with the linker in dark blue. The mutation sites are 
labeled in red on the model. (B) The structural models of insert region and C-terminal portion of 
hFMO3 built by Phyre2. (C) Hydrogen bonds involving S195 and E32 residues with NADP+ and 
FAD, respectively. (D) The surface representation of hFMO3 docked with trimethylamine (colored 
in yellow). The FAD is shown in magenta with mutation sites in green. Figures were generated with 
PyMOL. 
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Figure 3 
 
 
 
 
 
 
 
(A) Graphical representation of RMSD of the simulation trajectory of Cα atoms showing the 
structural stability of hFMO3 after 2 ns of MD simulation. 
(B) RMSF per residue plot for hFMO3 with four highly flexible regions; V110-H150 (cyan), V220-
A250 (blue), P400-Y430 (magenta) and P450-T532 (red). Figure inserts show these regions are 
located on the surface of the structure and exposed to the solvent. 
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Figure 4 
 
 
 
 
 
(A) Time course of trypsin digestion of purified hFMO3. Samples were analysed by 12.5% SDS-
PAGE. (B) Cartoon representation and (C) surface representation of the possible enzyme digestion 
sites based on trypsin digestion banding pattern are labeled on hFMO3 model. Figures were prepared 
by PyMOL. 
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Figure 5 
 
 
 
 
 
(A) Substrates used for docking experiments were built and optimized using DS Visualizer. Binding 
modes of hFMO3-substrate complexes performed by YASARA Structure package.  
Molecular docking experiments with hFMO3-Benzydamine (B); hFMO3-Tozasertib (C); hFMO3-
Trimethylamine (D); hFMO3-Methimazole (E); hFMO3-Sulindac sulfide (F). Substrate binding site 
residues are shown as sticks and colored in cyan. Substrates are colored in yellow, and FAD is shown 
in orange.  Pi-stacking, Pi-sigma, Pi-charge and Pi-sulfur interactions are shown as dotted black, 
blue, red and yellow lines, respectively. The conventional hydrogen bond, carbon hydrogen bond and 
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Pi-donor hydrogen bonds are shown in dotted orange, green and cyan lines, respectively. The 
interactions were monitored by DS Visualizer, and figures were generated with PyMOL.  
 
 
